Edema macular por tratamiento con rosiglitazona en diabetes mellitus

Asensio-Sánchez, V.M.; Asensio-Sánchez, M.J.; Gómez-Ramírez, V.

doi:10.1016/j.oftal.2010.09.001

Cited by 4 publications

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Drug-Induced Macular Edema

Makri

Georgalas

Georgakopoulos

2013

Drugs

View full text Add to dashboard Cite

Macular edema constitutes a serious pathologic entity of ophthalmology resulting in vision loss with a remarkable impact on the quality of life of patients. It is the final common pathway of various systemic diseases and underlying intraocular conditions, with diabetes mellitus being the most frequent cause. Other causes include venous occlusive disease, intraocular surgery, and inflammatory conditions of the posterior segment of the eye. Macular edema is a recognized side effect of various systemic and local medications and requires special consideration among ophthalmologists and other clinicians. Recently, antidiabetic thiazolidinediones have been implicated in the development of macular edema, and a review of the English literature revealed that other systemically administered drugs like fingolimod, recently approved for relapsing forms of multiple sclerosis, the anticancer agents tamoxifen and the taxanes, as well as niacin and interferons have been reported to cause macular edema. Ophthalmologic pharmaceutical agents, like prostaglandin analogs, epinephrine, timolol, and ophthalmic preparation preservatives have also been reported to cause macular edema as an adverse event. The purpose of this article is to provide a short, balanced overview of the available evidence in this regard. The available data and the possible pathophysiologic mechanisms leading to the development of macular edema are discussed. Possible therapeutic strategies for drug-induced macular edema are also proposed.

show abstract

Drug-Induced Macular Edema

Makri

Georgalas

Georgakopoulos

2013

Drugs

View full text Add to dashboard Cite

show abstract

Thiazolidinediones

2016

Meyler's Side Effects of Drugs

View full text Add to dashboard Cite

Synthesis and biological evaluation of the new 1,3-dimethylxanthine derivatives with thiazolidine-4-one scaffold

Constantin

Lupașcu

Apotrosoaei

et al. 2017

Chemistry Central Journal

View full text Add to dashboard Cite

BackgroundThe xanthine structure has proved to be an important scaffold in the process of developing a wide variety of biologically active molecules such as bronchodilator, hypoglycemiant, anticancer and anti-inflammatory agents. It is known that hyperglycemia generates reactive oxygen species which are involved in the progression of diabetes mellitus and its complications. Therefore, the development of new compounds with antioxidant activity could be an important therapeutic strategy against this metabolic syndrome.ResultsNew thiazolidine-4-one derivatives with xanthine structure have been synthetized as potential antidiabetic drugs. The structure of the synthesized compounds was confirmed by using spectral methods (FT-IR, 1H-NMR, 13C-NMR, 19F-NMR, HRMS). Their antioxidant activity was evaluated using in vitro assays: DPPH and ABTS radical scavenging ability and phosphomolybdenum reducing antioxidant power assay. The developed compounds showed improved antioxidant effects in comparison to the parent compound, theophylline. In the case of both series, the intermediate (5a–k) and final compounds (6a–k), the aromatic substitution, especially in para position with halogens (fluoro, chloro), methyl and methoxy groups, was associated with an increase of the antioxidant effects.ConclusionsFor several thiazolidine-4-one derivatives the antioxidant effect of was superior to that of their corresponding hydrazone derivatives. The most active compound was 6f which registered the highest radical scavenging activity.Graphical abstractDesign and synthesis of new thiazolidine-4-one derivatives. Electronic supplementary materialThe online version of this article (doi:10.1186/s13065-017-0241-0) contains supplementary material, which is available to authorized users.

show abstract

Edema macular por tratamiento con rosiglitazona en diabetes mellitus

Cited by 4 publications

References 6 publications

Drug-Induced Macular Edema

Drug-Induced Macular Edema

Thiazolidinediones

Synthesis and biological evaluation of the new 1,3-dimethylxanthine derivatives with thiazolidine-4-one scaffold

Contact Info

Product

Resources

About